IASLC TTLC 2022 | Evaluating the role of systemic therapies in SCLC

Triparna Sen, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the role of systemic therapies in treating patients with small cell lung cancer (SCLC). As patients with SCLC are typically diagnosed in the advanced stages, surgery is no longer viable due to metastasis. Most patients will respond to systemic therapies such as chemotherapy and immunotherapy, but recurrence can occur in a number of patients, especially when the disease has metastasized. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).